Amphastar Pharmaceuticals Inc. announced that its wholly-owned subsidiary has entered into a Distribution Agreement with Nanjing Chengong Pharmaceutical Co., Limited, a subsidiary of Nanjing Hanxin Pharmaceutical Technology Co., Ltd. Under the terms of the ten-year agreement, Chengong will serve as the exclusive distributor of Amphastar's nasal powder product, BAQSIMI®, in Mainland China, Taiwan, Hong Kong, and Macau. Chengong will be responsible for obtaining regulatory approvals and conducting required post-marketing clinical trials in the region. The agreement includes minimum purchase commitments, a profit-sharing arrangement above a set floor price per unit, and obligations regarding data safety and quality control. Both parties have rights to terminate the agreement without cause after the fourth contract year. Payments under the agreement will be made in U.S. dollars, and the total revenue over the ten-year period is currently undeterminable. The agreement was approved by the independent members of Amphastar's Audit Committee due to related party considerations.